HOME
CAREER NETWORK
NEWS
HOTBEDS
EVENT CENTER
CAREER FAIRS
COMPANY PROFILES
RESEARCH STORE
ABOUT US
NEWSLETTERS Free Newsletters Archive My eNewsletters NEWS News by Subject News by Disease News by Date PLoS Search News Post Your News JoVE CAREER NETWORK Job Seeker Login Most Recent Jobs Search Jobs Post Resume Career Fairs Career Resources For Employers COMMUNITY Login Become a Member Discussion Forums FAQ HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia BIOTECH WORK PORTAL Career Definitions Labor Market Reports Education & Training Regions DIVERSITY INVESTOR Market Summary News IPOs PROFILES Company Profiles START UPS Companies Events INTELLIGENCE Research Store INDUSTRY EVENTS Biotech Events Post an Event RESOURCES Real Estate Business Opportunities
<script language="javascript" src="http://at.ontargetjobs.com/addyn/3.0/701/1475036/0/681/ADTECH;loc=700;target=_blank;key=key1+key2+key3+key4;grp=[group]"></script><noscript><a href="http://at.ontargetjobs.com/adlink/3.0/701/1475036/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" target="_blank"><img src="http://at.ontargetjobs.com/adserv/3.0/701/1475036/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" border="0" width="160" height="240"></a></noscript>
ScienceDaily (June 24, 2009) — A report in Cancer Research highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.